|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hinweise |
|
|
|
Wiss. Komitee |
|
|
|
Adressen |
|
|
|
Presse |
|
|
|
Öffnungszeiten |
|
|
|
Gesellschaften |
|
|
|
Hotelreservierung |
|
|
|
Termine |
|
|
|
Rahmenprogramm |
|
|
|
Gebühren |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Online-Anmeldung
Online-Abstracts
Kontakt-Adressen
Congress Center Leipzig
zurück zum Start
Programm-Schwerpunkte-Gesellschaften
|
Symposium 18 Moderne Therapieaspekte der Sepsis |
||
|
10.30 – 12.00 |
Vorsitz H. Link; Kaiserslautern, H. Riess; Berlin |
|
|
Level 1 – Raum 5 |
|
|
|
04.05.2001 |
Sy 18.01 |
Therapie der schweren Sepsis mit aktiviertem Protein C |
|
10.30 |
H. Riess; Berlin |
|
|
Sy 18.02 |
AT III: Einfluss auf Leukozyten und Mediatoren der Sepsis – Ergebnisse der KyberSept-Studie |
|
|
10.50 |
J. Hoffmann; München |
|
|
Sy 18.03 |
TIFPI: Sepsistherapie mit tissue factor pathway inhibitor |
|
|
11.10 |
K. Reinhart; Jena |
|
|
Sy 18.04 |
Key note ==> Stellenwert der Immunglobulintherapie bei Sepsis |
|
|
11.30 |
G. Kreymann; Hamburg |
|
|
Mit freundlicher Unterstützung durch Aventis Behring Pharma und Biotest Pharma |
||